In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson’s disease

Abstract Direct targeting of alpha-synuclein (ASYN) has emerged as a disease-modifying strategy for Parkinson’s disease and other synucleinopathies which is being approached using both small molecule compounds and ASYN-targeted biologics. Minzasolmin (UCB0599) is an orally bioavailable and brain-pen...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Diana L. Price, Asma Khan, Rachel Angers, Alvaro Cardenas, Maria Key Prato, Massimo Bani, Douglas W. Bonhaus, Martin Citron, Anja-Leona Biere
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Nature Portfolio 2023-07-01
coleção:	npj Parkinson's Disease
Acesso em linha:	https://doi.org/10.1038/s41531-023-00552-7
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!